#elijilly

1 story

#capital markets day #glp-1 #nfl #novo nordisk #obesity drugs #ozempic #patent cliff #semaglutide #stock market #viking therapeutics #wegovy

Novo Nordisk Stock Drops 7% After Growth Plan Fails to Ease Competition Fears
Novo Nordisk's stock falls 7% as its post-Wegovy growth plan fails to reassure investors about competition risks
24/7 Wall St. · 1m